FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages
- PMID: 22109743
- DOI: 10.1007/s00198-011-1838-0
FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages
Abstract
Summary: The hormone fibroblast growth factor 23 (FGF23) is involved in mineral homeostasis but may also have a role in vascular calcification and bone mineralization. In a cohort of 142 patients with CKD stages 2-5D, plasma FGF23 was independently associated with aortic calcification but not with pulse wave velocity or bone mineral density.
Introduction: FGF23 is involved in mineral homeostasis but may also have a role in vascular calcification and bone mineralization. Previous studies related to FGF23 and vascular and bone outcomes have been restricted to dialysis patients. The aim of the present study was to establish whether or not plasma FGF23 is associated with aortic and coronary calcification, arterial stiffness, and bone mineral density in patients with early as well as late stages of CKD.
Methods: In a cohort of 142 patients with CKD stages 2-5D, we made routine biochemistry and intact FGF23 determinations, and assessed aortic and coronary calcification, bone mineral density (BMD), and arterial stiffness by multislice spiral computed tomography and automated pulse wave velocity (PWV).
Results: Plasma intact FGF23 levels were elevated in CKD patients; the elevation preceded that of serum phosphate in early-stage CKD. Patients with elevated FGF23 levels had higher aortic and coronary calcification scores than patients with lower FGF23 levels. Multivariate linear regression analysis indicated that only age (p < 0.001) and FGF23 (p = 0.008) were independently associated with aortic calcification score. Plasma FGF23 was neither associated with PWV nor with BMD.
Conclusion: Our data suggest that plasma FGF23 is an independent biomarker of vascular calcification in patients with various CKD stages including early stages. The association between vascular calcification and FGF23 levels appears to be independent of BMD. It remains to be seen whether this association is independent of bone turnover and bone mass.
Comment in
-
FGF23: instability may affect accuracy and interpretation.Osteoporos Int. 2013 Mar;24(3):1135-6. doi: 10.1007/s00198-012-2036-4. Epub 2012 Aug 9. Osteoporos Int. 2013. PMID: 22875457 No abstract available.
-
Lack of predictive value of FGF23 levels on pulse wave velocity.Osteoporos Int. 2013 Mar;24(3):1137. doi: 10.1007/s00198-012-2037-3. Epub 2012 Aug 9. Osteoporos Int. 2013. PMID: 22875458 No abstract available.
Similar articles
-
Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.BMC Nephrol. 2017 Sep 4;18(1):281. doi: 10.1186/s12882-017-0705-4. BMC Nephrol. 2017. PMID: 28870151 Free PMC article.
-
Chronic Kidney Disease-Mineral Bone Disorder in Korean Patients: a Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).J Korean Med Sci. 2017 Feb;32(2):240-248. doi: 10.3346/jkms.2017.32.2.240. J Korean Med Sci. 2017. PMID: 28049234 Free PMC article.
-
Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.Am J Nephrol. 2020;51(3):201-215. doi: 10.1159/000505717. Epub 2020 Feb 5. Am J Nephrol. 2020. PMID: 32023606 Clinical Trial.
-
[Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].Clin Calcium. 2015 May;25(5):645-53. Clin Calcium. 2015. PMID: 25926567 Review. Japanese.
-
FGF23 and Phosphate-Cardiovascular Toxins in CKD.Toxins (Basel). 2019 Nov 6;11(11):647. doi: 10.3390/toxins11110647. Toxins (Basel). 2019. PMID: 31698866 Free PMC article. Review.
Cited by
-
Vascular calcification: pathophysiology and risk factors.Curr Hypertens Rep. 2012 Jun;14(3):228-37. doi: 10.1007/s11906-012-0265-8. Curr Hypertens Rep. 2012. PMID: 22476974 Free PMC article. Review.
-
Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality.Diabetol Metab Syndr. 2024 Sep 6;16(1):217. doi: 10.1186/s13098-024-01440-7. Diabetol Metab Syndr. 2024. PMID: 39238022 Free PMC article. Review.
-
Vascular calcification: When should we interfere in chronic kidney disease patients and how?World J Nephrol. 2016 Sep 6;5(5):398-417. doi: 10.5527/wjn.v5.i5.398. World J Nephrol. 2016. PMID: 27648404 Free PMC article. Review.
-
The Growth Factors: Potential Biomarkers and Therapeutic Targets in Kidney Diseases.Kidney Dis (Basel). 2022 Sep 12;8(5):368-380. doi: 10.1159/000526208. eCollection 2022 Nov. Kidney Dis (Basel). 2022. PMID: 36466071 Free PMC article. Review.
-
Label-free quantitative proteomics identifies Smarca4 is involved in vascular calcification.Ren Fail. 2019 Nov;41(1):220-228. doi: 10.1080/0886022X.2019.1591997. Ren Fail. 2019. PMID: 30973285 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical